自体DC-CIK免疫疗法治疗非小细胞肺癌患者的效果及对肺功能的影响

鄢清元 熊巍 杨文平

【摘要】 目的：探討自体DC-CIK免疫疗法治疗非小细胞肺癌患者的效果及对患者肺功能的影响。方法：选取2019年12月-2020年12月于本院治疗的非小细胞肺癌患者74例。随机分为对照组和研究组，每组37例。对照组应用NP化疗，研究组在此基础上应用自体DC-CIK免疫疗法。比较两组免疫功能、肺功能和凝血功能情况。结果：治疗后，研究组CD4+、CD3+、NK均高于对照组，CD8+低于对照组，差异均有统计学意义（P<0.05）。治疗后，两组的FEV1/FVC比较，差异无统计学意义（P>0.05）;治疗后，研究组FVC、FEV1均高于对照组，差异均有统计学意义（P<0.05）。治疗后，研究组PLT、PT、FIB均低于对照组，差异均有统计学意义（P<0.05）。结论：非小细胞肺癌患者应用自体DC-CIK免疫疗法治疗效果较好，可以有效提高患者的机体免疫力，改善凝血功能和肺功能，有利于疾病的控制，从而提高治疗效果。

【关键词】 非小细胞肺癌 自体DC-CIK免疫疗法 肺功能

The Effect of Autologous DC-CIK Immunotherapy on Patients with Non-small Cell Lung Cancer and Its Influence on Lung Function/YAN Qingyuan， XIONG Wei， YANG Wenping. //Medical Innovation of China， 2021， 18（16）： 0-082

[Abstract] Objective： To explore the effect of autologous DC-CIK immunotherapy in the treatment of patients with non-small cell lung cancer and its influence on the lung function of patients. Method： Select 74 patients with non-small cell lung cancer who were treated in our hospital from December 2019 to December 2020. They were randomly divided into control group and study group， with 37 cases in each group. The control group was treated with NP chemotherapy， and the study group was treated with autologous DC-CIK immunotherapy on this basis. The immune function， lung function and blood coagulation function of the two groups were compared. Result： After treatment， the CD4+， CD3+ and NK of the study group were higher than those of the control group， and CD8+ was lower than the control group， the differences were statistically significant （P<0.05）. After treatment， there was no significant difference in FEV1/FVC between the two groups （P>0.05）. After treatment， FVC and FEV1 in the study group were higher than those in the control group， the differences were statistically significant （P<0.05）. After treatment， the PLT， PT and FIB of the study group were lower than those of the control group， and the differences were statistically significant （P<0.05）. Conclusion： The effect of autologous DC-CIK immunotherapy for patients with non-small cell lung cancer is better， which can effectively improve the patient’s immunity， improve coagulation function and lung function， and help control the disease， thereby improving the therapeutic effect.

[Key words] Non-small cell lung cancer Autologous DC-CIK immunotherapy Lung function

First-author’s address： Fengcheng People’s Hospital， Fengcheng 331100， China

doi：10.3969/j.issn.1674-4985.2021.16.019

临床中常见的一种恶性肿瘤就是肺癌，其中发病率占比最高的就是非小细胞肺癌（NSCLC），此类患者疾病症状不明显，容易忽视，因此确诊时通常已经处于中晚期，主要的治疗方法即放化疗，但在延长生存期方面效果不佳[1]。肿瘤的治疗在临床中的重视程度越来越高，如今治疗的方法较多，而免疫治疗成为肿瘤治疗的首选方式，效果较好[2]。树突状细胞（DC）是机体中主要的且功能最强大的一种抗原递呈细胞，可以诱导淋巴细胞反应，与此同时对β细胞的增殖有抑制作用，将免疫应答活化;而细胞因子诱导杀伤细胞（CIK）是高效且新型的免疫效应细胞，有广谱杀瘤活性，可以有效改善机体的免疫功能，具有较强的肿瘤杀伤力[3]。……